We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Activist hedge fund Starboard Value is “certainly interested in the story at Bristol-Myers,” according to its leader. But that doesn’t mean it’s getting involved.
The Delaware Supreme Court on Friday upheld a lower court ruling permitting Fresenius Kabi to terminate its agreement to acquire Akorn for more than $4 billion. Shares in the latter drugmaker were down as much as 37 percent on the news.